Patent applications published 13 April 2011

Published: 28-Apr-2011

Selected patent applications from the weekly European Patents Bulletin


  • Formulations of 5-fluorocysteine and uses thereof
    Tocagen 2306823*

  • Iontophoretic delivery of curcumin and curcumin analogues for the treatment of Alzheimer’s disease
    Codman and Surtleff 2306824*

  • Inhibitors of AKT activity
    GlaxoSmithKline 2306825*

  • Salts of methyl 2-((R))-(3-chloro-phenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
    Vitae Pharmaceuticals 2306826*

  • Prolyl hydroxylase inhibitors
    GlaxoSmithKline 2306828*

  • Particles containing an opioid receptor antagonist and methods of use
    University of Chicago 2306829*

  • Use of mifepristone for the treatment of amyotrophic lateral sclerosis
    Corcept Therapeutics 2306830*

  • BMI-1 protein expression modulators
    PTC Therapeutics 2306836*

  • Compsn for external skin application containing pine knot extract and method for preparation of the same
    Amorepacific 2306969*

  • Unit dosage of apadenoson
    University of Virginia Patent Foundation 2306971*

  • Acetic acid and a buffer
    Danmarks Tekniske Universiteit 2306972*

  • Vaginal suppository comprising lactic acid
    Rolf Kullgren 2306973*

  • A topical compsn comprising the isolated non-polar lipid fraction of lanolin4
    Universiteit Leiden; Universiteit Utrecht Holding; Stichting Voor de Technische Wetenschappen 2306974*

  • Controlled release otic structure modulating and innate immune system modulating compsns and methods for the treatment of otic disorders
    Otonomy; The Regents of the University of California 2306975*

  • Injectable taxane pharmaceutical compsn
    GP Pharm 2306976*

  • Method and compsn for treating ocular hypertension and glaucoma
    Santen Pharmaceutical; Asahi Glass 2306977*

  • Compsns for the in vivo delivery of RNAI agents
    Mirna Therapeutics 2306978*

  • Liposomes capable of effectively binding the beta amyloid peptide
    Università Degli Studi di Milano - Bicocca 2306979*

  • Powders for reconstitution
    Tibotec Pharmaceuticals 2306980*

  • A transmucosal delivery system
    University of the Witwatersrand 2306981*

  • Pharmaceutical compsns of rosuvastatin calcium
    Abdi Ibrahim Ilas Sanayi Ve Ticaret Anonim Sirketi 2306982*

  • A gastroretentive pharmaceutical dosage form
    University of the Witwatersrand 2306983*

  • Pharmaceutical dosage form for the site-specific delivery of more than one active pharmaceutical ingredient
    University of the Witwatersrand 2306984*

  • Controlled release compsns of agents that reduce circulating levels of platelets and methods therefor
    Biovascular 2306985*

  • Prodrugs and drug-macromolecule conju-gates having controlled drug release rates
    Prolynx 2306986*

  • Method for coating tablets
    BASF 2306987*

  • Pharmaceutical formulation for treating the upper digestive tract
    Dr Falk Pharma 2306988*

  • Fenofibrate formulation with enhanced oral bioavailability
    Panacea Biotec 2306989*

  • Pharmaceutical compsn comprising N-[2-(diethylamino_ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
    Ratiopharm 2306990*

  • Injectable delivery of microparticles and compsns therefore
    Tepha; Surmodics Pharmaceuticals 2306991*

  • Delivery particle
    Appleton Papers 2306992*

  • Protamine/RNA nanoparticles for immunostimulation
    Universität Zurich 2306993*

  • S1P1 receptor agonists and use thereof
    Amgen 2306994*

  • Antitumour properties of NO modified protease inhibitors
    Ganial Immunotherapeutics 2306995*

  • Use of HDAC inhibitors for the treatment of Hodgkin’s disease
    Novartis 2306996*

  • Treatment of ringworm
    Vernolix 2306997*

  • Pharmaceutical formulation
    Alphapharm 2306998*

  • Compsns for treating rosacea
    Polichem 2306999*

  • Combination of pilocarpin and methimazol for treating charcot-marie-tooth disease and related disorders
    Pharnext 2307000*

  • Control of blood vessel physiology to treat skin disorders
    BioChemics 2307001*

  • Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
    Cyclacel 2307002*

  • Combination therapy with PM00104 and another antitumour agent
    Pharma Mar 2307003*

You may also like